Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have received an average rating of “Moderate Buy” from the six analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $11.40.

A number of equities research analysts recently commented on the stock. Royal Bank of Canada reduced their price objective on shares of Verrica Pharmaceuticals from $13.00 to $11.00 and set an “outperform” rating for the company in a research report on Friday, October 4th. TD Cowen reduced their price target on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a report on Monday, October 21st. Brookline Capital Management restated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, October 2nd. Finally, Needham & Company LLC reiterated a “hold” rating and issued a $12.00 price objective on shares of Verrica Pharmaceuticals in a research report on Thursday, October 3rd.

Verrica Pharmaceuticals Price Performance

Verrica Pharmaceuticals stock opened at $1.51 on Monday. The company has a debt-to-equity ratio of 29.58, a current ratio of 2.36 and a quick ratio of 2.23. The business has a 50 day simple moving average of $1.86 and a 200-day simple moving average of $5.44. Verrica Pharmaceuticals has a 12 month low of $1.04 and a 12 month high of $11.41. The stock has a market capitalization of $64.05 million, a PE ratio of -0.86 and a beta of 1.45.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. The company had revenue of $5.18 million during the quarter, compared to the consensus estimate of $4.70 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. Equities analysts predict that Verrica Pharmaceuticals will post -1.58 earnings per share for the current year.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Simplify Asset Management Inc. acquired a new stake in Verrica Pharmaceuticals in the second quarter valued at $2,041,000. Renaissance Technologies LLC acquired a new stake in Verrica Pharmaceuticals in the 2nd quarter valued at about $332,000. Quest Partners LLC purchased a new position in Verrica Pharmaceuticals during the 2nd quarter valued at about $50,000. Rhumbline Advisers raised its position in Verrica Pharmaceuticals by 20.4% during the second quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock worth $194,000 after acquiring an additional 4,514 shares during the last quarter. Finally, Key Financial Inc purchased a new stake in shares of Verrica Pharmaceuticals in the second quarter valued at about $69,000. 42.45% of the stock is owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.